Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common stock	Additional paidin capital	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Beginning of period at Dec. 31, 2022	$ 19	$ 288,361	$ 150	$ (274,225)	$ 14,305
Balance at Beginning of period (in shares) at Dec. 31, 2022	19,165,027
Vesting of restricted stock units and exercise of stock options		127			127
Vesting of restricted stock units and exercise of stock options (in shares)	126,987
Issuance of common stock under the employee stock purchase plan		88			88
Issuance of common stock under the employee stock purchase plan (in shares)	10,602
Shares withheld for employee taxes		(289)			(289)
Shares withheld for employee taxes (in shares)	(27,131)
Foreign currency translation adjustment			(59)		(59)
Stock-based compensation expense		5,032			5,032
Sale of common stock, net of underwriting discounts, commissions and offering costs	$ 5	46,336			46,341
Sale of common stock, net of underwriting discounts, commissions and offering costs (in shares)	5,219,190
Net loss				(46,664)	(46,664)
Balance at Ending period at Dec. 31, 2023	$ 24	339,655	91	(320,889)	18,881
Balance at Ending period (in shares) at Dec. 31, 2023	24,494,675
Vesting of restricted stock units and exercise of stock options	$ 1	225			226
Vesting of restricted stock units and exercise of stock options (in shares)	229,606
Issuance of common stock under the employee stock purchase plan		281			281
Issuance of common stock under the employee stock purchase plan (in shares)	58,994
Shares withheld for employee taxes		(369)			(369)
Shares withheld for employee taxes (in shares)	(57,563)
Foreign currency translation adjustment			(1)		(1)
Stock-based compensation expense		4,362			4,362
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs	$ 14	42,905			42,919
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs (in shares)	14,670,000
Net loss				(37,841)	(37,841)
Balance at Ending period at Dec. 31, 2024	$ 39	387,059	90	(358,730)	28,458
Balance at Ending period (in shares) at Dec. 31, 2024	39,395,712
Vesting of restricted stock units	$ 1				1
Vesting of restricted stock units (in shares)	279,765
Issuance of common stock under the employee stock purchase plan		105			105
Issuance of common stock under the employee stock purchase plan (in shares)	58,235
Shares withheld for employee taxes		(205)			(205)
Shares withheld for employee taxes (in shares)	(84,448)
Issuance of common stock warrants in connection with credit facility		1,413			1,413
Exercise of pre-funded warrant		(1)			(1)
Exercise of pre-funded warrant (in shares)	700,000
Foreign currency translation adjustment			1		1
Stock-based compensation expense		3,796			3,796
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs	$ 4	11,572			11,576
Sale of common stock and pre-funded warrants, net of underwriting discounts, commissions and offering costs (in shares)	4,189,000
Net loss				(38,831)	(38,831)
Balance at Ending period at Dec. 31, 2025	$ 44	$ 403,739	$ 91	$ (397,561)	$ 6,313
Balance at Ending period (in shares) at Dec. 31, 2025	44,538,264